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Rapid Communication
Successful treatment of hypercalcemia with cinacalcet in renal
transplant recipients with persistent hyperparathyroidism
Andreas L. Serra, Albin A. Schwarz, Franziska H. Wick, Hans-Peter Marti and Rudolf P. Wu¨thrich
Division of Nephrology, University Hospital, Ra¨mistrasse 100, 8091 Zu¨rich, Switzerland
Abstract
Background. Cinacalcet lowers plasma parathyroid
hormone (PTH) levels in primary and secondary
hyperparathyroidism. The efﬁcacy and safety of
cinacalcet have not been examined in renal transplant
patients with persistent hyperparathyroidism. The
aim of this study was to evaluate the effect of
cinacalcet as a novel therapy for the management of
such patients.
Methods. Eleven renal allograft recipients with persis-
tent hyperparathyroidism were treated with cinacalcet.
The total study time was 10 weeks. Individual
cinacalcet doses were adjusted to obtain a serum
calcium in the predeﬁned normal target range of
2.10–2.60mmol/l.
Results. Serum calcium decreased signiﬁcantly
from 2.73±0.05mmol/l to 2.44±0.05 and 2.42±
0.04mmol/l after 2 and 10 weeks of treatment,
respectively. All patients reached the target range
rapidly and remained normocalcaemic throughout
the study. Serum PTH signiﬁcantly decreased 16.1
and 21.8% at study weeks 2 and 10, respectively,
compared with week 0. Serum phosphate increased.
Renal function remained stable and no allograft
rejection was observed. From weeks 2 to 10, daily
cinacalcet doses administered were 30mg (n¼ 8),
15mg (n¼ 1) and 60mg (n¼ 1), respectively.
Conclusion. Cinacalcet was effective in correcting
the hypercalcaemia associated with persistent hyper-
parathyroidism after renal transplantation. It appears
to be safe. Thus, cinacalcet represents a promising
alternative for parathyroidectomy in these patients.
Keywords: calcium; cinacalcet; hypercalcaemia;
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Introduction
Tertiary hyperparathyroidism is common after renal
transplantation [1,2]. The disorder is characterized by
persistently elevated serum calcium and increased or
inappropriately high-normal parathyroid hormone
(PTH) levels. Parathyroidectomy represents the deﬁni-
tive treatment for persistent hyperparathyroidism
and is recommended for symptomatic hypercalcaemia,
or if the plasma calcium concentration remains
abnormal for >1 year [3,4]. Many patients remain
untreated because they do not meet the accepted
guidelines for parathyroidectomy or do not wish to
have surgery. Nevertheless, they may be at increased
risk for bone disease and vascular calciﬁcation.
In primary [5,6] and secondary [7] hyperparathy-
roidism, the calcimimetic drug cinacalcet effectively
lowers PTH levels. Since the efﬁcacy and safety of
cinacalcet in patients with a functioning kidney graft
have not been studied, we designed a prospective study
to examine the effect of cinacalcet on serum calcium
and PTH levels in renal allograft recipients with
persistent hyperparathyroidism.
Methods
Patients and study design
A prospective single centre, open label study was performed
in 11 renal transplant recipients with persistent hyperpara-
thyroidism and normal allograft function. The study was
approved by the local ethics committee. All patients gave
written informed consent. Patients were included if they met
all of the following criteria: total serum calcium 2.60mmol/l
(measured at least twice within 6 months, normal range,
2.10–2.60mmol/l), plasma intact PTH concentration65 ng/l
(normal range, 15–65 ng/l), duration of renal transplanta-
tion 6 months, 18 years of age, measured creatinine
clearance (CrCl) 40ml/min/1.73m2, normal serum 1,25-
dihydroxyvitamin D (normal range, 19.0–67.0 ng/l) and
25-hydroxyxvitamin D (normal range, 10–42mg/l) levels,
and stable maintenance immunosuppressive therapy over
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the last 6 months. Dietary calcium intake was not restricted
but kept stable during the course of the study. Diuretics
were not permitted during the study period. Exclusion
criteria included pregnancy, elevated liver enzymes (serum
aspartate aminotransferase and alanine aminotransferase),
concurrent or preceding (within 3 months of inclusion)
therapy with ﬂecainide, thioridazine, bi- or tricyclic anti-
depressants, vitamin D sterols, calcium supplementation,
bisphophonates or ﬂuoride, and clinically suspected or
biopsy-proven renal allograft rejection within 6 months
before study start.
After inclusion, patients received 30mg of cinacalcet
once daily in the evening. The cinacalcet dosage was adapted
every 2 weeks to keep the serum calcium in the predeﬁned
target range of 2.10–2.60mmol/l independently of intact
PTH level. Oral phosphate supplementation was stopped if
the serum phosphate level was >0.87mmol/l (normal range,
0.87–1.45mmol/l). Blood pressure was measured at every
study visit by an automatic blood pressure monitor
(Boso-Medicus, Jungingen, Germany). The total study time
was 10 weeks.
Laboratory analyses
Blood samples were collected for measurements of serum
total and ionized calcium, serum phosphate, plasma intact
PTH, plasma creatinine, serum urea, serum albumin, whole
blood trough level of cyclosporin or tacrolimus and liver
enzymes every 2 weeks after an overnight fast and before
the administration of the immunosuppressive drugs. The
glomerular ﬁltration rate was calculated every 2 weeks
according to the Modiﬁcation of Diet in Renal Disease
(MDRD) study group using the following values: plasma
creatinine, serum urea, serum albumin, gender, race and
age [8]. Urine was collected over 24 h at baseline and at
week 10 for the measurement of creatinine clearance and
fractional calcium and phosphate excretion rates. Calcium,
phosphate and liver enzymes were measured by standard
methods, creatinine by the modiﬁed Jaffe´ method and plasma
intact PTH using a double antibody chemiluminescence
immunoassay (Roche Diagnostics Switzerland). Serum
1,25-dihydroxyvitamin D and 25-hydroxyxvitamin D were
measured by radioreceptor assay, and the whole blood
concentration of cyclosporin and tacrolimus by immuno-
assay. All biochemical analyses were performed at the
Department of Clinical Chemistry of our institution.
Statistical analysis
Means of continuous data were compared by the Student’s
t-test. P-values were two sided for the comparison with the
baseline value, and those <0.05 were considered statistically
signiﬁcant. All laboratory results have been expressed as
means±SE. Values that were not normally distributed were
expressed as medians (minimum–maximum). All analyses
were performed using SPSS software (version 12.0, SPSS Inc.,
Chicago, IL).
Results
Relevant demographic, clinical and laboratory features
of our patients are presented in Table 1. All patients
were Caucasians. Patient no. 3 had undergone para-
thyroidectomy 4 years ago. Three patients were on oral
phosphate supplementation at study inclusion. One
patient (no. 9) discontinued the study after 2 weeks
because of visual problems (see below).
Serum calcium and phosphate concentration
and plasma intact PTH level
Prior to inclusion, all patients had persistent hypercal-
caemia (Figure 1). After the individual cinacalcet doses
were adjusted at week 2, total serum calcium remained
within normal limits and ionized calcium<1.35mmol/l
in all patients until week 10 (Figures 1 and 2A).
Importantly, no further cinacalcet dose adjustment
Table 1. Patient demographics and characteristics at baseline (week 0)
No. Age
(years)
Sex Dialysis
(months)
Time from RTx to
study week 0 (months)
Creatinine clearance
(ml/min/1.73m2)
Immunosuppression
1 51 M 36 6 69.92 CyAþMMFþPDN
2 64 M 30 17 45.56 CyAþMMF
3 49 F 45 29 49.37 TacþMMF
4 70 F 84 10 55.32 CyAþMMFþPDN
5 50 F 12 364 72.46 AzaþPDN
6 59 F 41 14 43.37 CyAþAza
7 61 M 0 28 68.35 CyAþMMF
8 55 F 0 37 43.20 CyAþMMF
9 62 F 35 28 49.14 CyAþMMF
10 70 M 29 178 61.92 CyAþAza
11 59 M 33 55 44.71 CyAþMMFþPDN
59.1±2.2 5 M, 6 F 33 (0–84) 28 (6–364) 54.84±3.42
RTx¼ renal transplantation; CyA¼ cyclosporin A; Tac¼ tacrolimus; MMF¼mycophenolate mofetil; Aza¼ azathioprine;
PDN¼prednisone.
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had to be performed. The applied daily dosages
of cinacalcet during the 8 weeks following the initial
dose-ﬁnding period were as follows: 30mg (n¼ 8),
15mg (n¼ 1) and 60mg (n¼ 1). Cinacalcet increased
serum phosphate concentrations signiﬁcantly at
study weeks 2, 8 and 10, although oral phosphate
supplements were stopped at week 6 (Figure 2B).
The serum calcium phosphate product remained
unchanged throughout the study (Figure 2C). Intact
PTH levels were reduced by 16.1% during the dose-
ﬁnding period and remained suppressed throughout the
study (Figure 3). The intact PTH levels from week 0 to
10 are indicated in Table 2.
Renal function and urinary excretion
of phosphate and calcium
Renal function was assessed by serum creatinine,
serum urea and calculated glomerular ﬁltration rate
according to the MDRD study group (extended
version) every 2 weeks, and creatinine clearance was
measured at baseline and week 10. Based on these
determinations, renal function remained stable
throughout (Table 2). No allograft rejection was
observed. Blood pressure remained unchanged.
Fractional phosphate excretion after 10 weeks of
treatment with cinacalcet did not change signiﬁcantly
(P¼ 0.151). Similary, the fractional excretion of
calcium, 24 h urine calcium to creatinine ratio and
24 h urine calcium excretion remained unchanged
compared with baseline values (Table 2).
Immunosuppressive drug dosage and
calcineurin inhibitor trough levels
Nine of the 11 patients were on a cyclosporin-based
immunosuppression regimen (Table 1). Cyclosporin
doses and trough levels remained unchanged through-
out (Table 3). The doses of tacrolimus, mycophenolate
mofetil, azathioprine and prednisone also remained
constant.
A
B
C
Fig. 2. Serum levels of ionized calcium, phosphate and total
calciumphosphate product. (A) Cinacalcet reduced ionized serum
calcium concentration signiﬁcantly throughout the study. Ionized
serum calcium remained below 1.35mmol/l in all patients from
weeks 2 to 10. (B) Cinacalcet increased the mean serum phosphate
concentration. The increase reached statistical signiﬁcance at weeks
2, 8 and 10 despite discontinuation of prior oral phosphate
supplements in two patients at week 6. (C) The mean serum total
calciumphosphate product remained unchanged throughout the
study period. ***P<0.001, **P<0.01, *P<0.05, compared with
week 0 (mean±SE).
Fig. 1. Serum levels of total calcium over time. Prior to inclusion,
patients had persistent hypercalcaemia (weeks 24 to 0). Cinacalcet
reduced serum calcium concentration signiﬁcantly, achieving
normocalcaemia in all patients (<2.60mmol/l) from weeks 2 to 10.
***P<0.001, **P<0.01, compared with week 0 (mean±SE).
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Adverse events
Cinacalcet was well tolerated. No speciﬁc side
effects were reported and no serious adverse events
occurred during the 10 week treatment phase.
All patients continued to take the study medications
without interruption, except one subject. This patient
discontinued the study after 2 weeks because she
feared a possible deterioration of a pre-existing
retinitis pigmentosa. Ophthalmological examination
showed no changes in vision compared with pre-
study tests.
Discussion
Our study demonstrated that cinacalcet treatment
was effective in normalizing serum calcium in renal
transplant patients with persistent hyperparathyroid-
ism. The effect was sustained over 10 weeks, and
renal graft function remained stable.
In primary hyperparathyroidism, cinacalcet admin-
istered twice daily was effective in normalizing serum
calcium levels in 73% of patients with a mean serum
calcium of 2.67mmol/l at baseline, and relatively
constant and well-preserved kidney function. As in
our study, serum calcium was normalized rapidly,
within 2 weeks. After individual doses of cinacalcet
had been established, 100% of our renal transplant
patients reached the predeﬁned normal target
range of a total serum calcium concentration of
2.10–2.60mmol/l.
Successful renal transplantation leading to normal-
ization of urinary phosphate excretion and renal
calcitriol production may reverse hyperparathyroidism
due to involution of the parathyroid glands [9]. This
process takes a few months to several years. Our
patients had persistently elevated serum calcium
concentrations in the 6 months before cinacalcet
treatment was started, and 63.7% of them were
transplanted since >2 years.
Cinacalcet effectively lowers plasma parathyroid
hormone levels in primary [5,6] and secondary [7]
hyperparathyroidism. In our study, a signiﬁcant
reduction of plasma intact PTH of 18% was
observed. In patients with primary hyperparathyroid-
ism, the reduction was only 8%, with a mean PTH at
Table 2. Patient biochemistry between study weeks 0 and 10
Parameter Study week
0 2 4 6 8 10
Plasma intact PTH (ng/l) 176.0±24.0 147.6±25.6 147.8±28.6 153.9±23.9 133.0±31.2 135.6±17.6
Serum creatinine (mmol/l) 118.8±10.0 123.5±10.0 122.5±10.0 126.8±13.1 121.7±15.8 125.7±12.9
Serum urea (mmol/l) 8.18±0.77 9.62±1.06 9.44±0.94 8.80±1.12 8.21±1.18 10.01±1.42
MDRD GFR (ml/min/1.73m2) 56.65±5.75 52.87±5.41 52.96±4.93 52.05±4.75 54.88±6.53 51.96±5.25
CrCl (ml/min/1.73m2) 54.49±2.55 48.61±4.22
24 h urine Ca to creatinine ratio 0.42±0.12 0.39±0.12
Fractional Ca excretion (%) 1.48±0.32 1.62±0.31
24 h urine P to creatinine ratio 2.89±0.52 2.41±0.15
Fractional phosphate excretion (%) 37.35±3.28 30.87±2.92
MDRD GFR¼ calculated glomerular ﬁltration rate according to the Modiﬁcation of Diet in Renal Disease study group (extended
version); CrCl¼measured creatinine clearance; Ca¼ calcium; P¼phosphate.
Fig. 3. Parathyroid hormone (PTH) levels over time. Cinacalcet
reduced intact PTH plasma levels, expressed as mean percentage of
initial PTH (100%¼ value of week 0) by 12.2% (week 6), 25.3%
(week 8) and 21.8% (week 10), respectively. ***P<0.001,
**P<0.01, *P<0.05, compared with week 0 (mean±SE).
Table 3. Cyclosporin (n¼ 9) dose and whole blood through levels of study weeks 0–10
Parameter Study week
0 2 4 6 8 10
Cyclosporin dose (mg/day) 188.9±13.9 188.9±13.9 193.8±14.0 200.0±17.1 206.3±15.7 200±18.3
Cyclosporin dose (mg/kg/day) 2.98±0.18 2.98±0.18 2.93±0.16 2.65±0.45 2.92±0.29 3.08±0.15
Cyclosporin trough level (mg/l) 110.0±13.0 114.9±15.2 111.6±22.3 115.83±9.4 121.7±6.2 119.8±10.4
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baseline of 120 ng/l, compared with a 43% reduction
in patients with secondary hyperparathyroidism and
a mean baseline plasma PTH of 643 ng/l [7]. The
development of hypercalcaemia correlates with the
hyperplasia and nodular transformation of the para-
thyroid gland [10]. The degree of PTH reduction
with cinacalcet treatment may reﬂect the degree of
parathyroid hyperplasia and nodular transformation,
with less reduction in patients with adenoma-like
formations of the parathyroid glands.
The reduction of intact PTH was accompanied by
an increase in serum phosphate concentration towards
normal values and a trend to a reduced fractional
phosphate excretion. An elevated serum calcium
phosphate product is a risk factor for cardiovascular
mortality, at least in haemodialysis patients [8]. In our
study, the observed increase in serum phosphate was
counterbalanced by the decrease in serum calcium
and therefore the serum calcium phosphate product
remained unchanged.
The reduction of intact PTH by cinacalcet could
reduce tubular calcium reabsorption, leading to
hypercalciuria and, if prolonged, increase the risk
for nephrolithiasis [11] and osteopenia [12]. However,
the 24 h urine calcium to creatinine ratios and 24 h
urine calcium excretion remained unchanged, as
compared with baseline values. A similar observation
was also made in patients treated with cinacalcet
for primary hyperparathyroidism [6]. The authors
suggested that the observed reduction in serum
calcium led to a decrease of ﬁltered calcium load that
compensated for the decrease in tubular calcium
reabsorption. This could explain why despite a reduc-
tion in plasma PTH, overall urinary calcium excretion
did not change.
During the observation period of our study, renal
function remained unchanged and no renal allograft
rejection was observed. Immunosuppression was
kept constant throughout. In vivo interaction data of
cinacalcet with immunosuppressive drugs are lacking.
Cinacalcet inhibits cytochrome P450 2D6 (CYP2D6)
and is metabolized by CYP3A4, CYP2D6 and
CYP1A2. Therefore, no interactions with the meta-
bolic transformation of cyclosporin or tacrolimus
were expected. The cyclosporin dose and whole blood
trough levels showed no relevant ﬂuctuations.
In conclusion, the results of this study demonstrate
that cinacalcet is efﬁcacious and safe in normalizing
serum calcium by lowering intact PTH in renal
allograft recipients with hypercalcaemia due to per-
sistent hyperparathyroidism. These beneﬁcial effects
were rapidly achieved and were sustained over
2 months. Thus, the treatment of persistent hyperpara-
thyroidism with cinacalcet may represent a valuable
alternative for parathyroidectomy in these patients.
The long-term effects and treatment duration remain
to be examined.
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